CA-XSOLLA
30.1.2024 10:01:29 CET | Business Wire | Press release
Shurick Agapitov, a visionary author and the Founder of Xsolla unveiled his groundbreaking new book, "Once Upon Tomorrow," today. This pioneering work offers a transformative and aspirational vision of the Metaverse, contrasting markedly with mainstream narratives. Agapitov's book is a thought-provoking journey into the possibilities and potential of the Metaverse, providing a unique perspective diverging from the views often presented at industry conferences and by technology CEOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130496363/en/
(Graphic: Business Wire)
"In 'Once Upon Tomorrow,' I present a vision of the Metaverse as a vast, inclusive, and transformative space. It's not just a digital frontier but a realm where creativity, innovation, and empowerment converge. This book is my invitation to creators, thinkers, and dreamers across the globe to join in shaping a future where technology amplifies human potential and fosters a world of limitless possibilities. The Metaverse, as I see it, is not about control or confinement but about unleashing the collective creativity and entrepreneurial spirit inherent in all of us," said Shurick Agapitov, Founder of Xsolla and acclaimed author of "Once Upon Tomorrow."
"Once Upon Tomorrow" delves into the untapped potential of the Metaverse, highlighting its capacity to unite emerging and legacy brands, create unforgettable consumer experiences, and enrich cultures globally. Agapitov emphasizes the Metaverse's role in democratizing opportunities and equal access to cutting-edge technologies. His vision extends beyond mere technological innovation, underscoring the Metaverse's potential to empower and reward content creators across the globe. The book also highlights the significant impact of the Metaverse on education, offering hope and opportunities for both children and adults worldwide. Agapitov advocates for a decentralized Metaverse moving away from Silicon Valley's dominance, placing control, profit potential, and freedom in the hands of creative communities.
"Once Upon Tomorrow" is more than just a book about the Metaverse; it's a roadmap to a future where technology serves humanity in all its diversity, fostering financial, social, and creative inclusivity. Agapitov envisions a future where every consumer-facing industry, from fashion to healthcare and entertainment, is transformed. The book also explores the potential impact of the Metaverse on business-to-business sectors, education, city planning, inter-government relations, and non-profit efforts.
Agapitov's insight into the evolution of technology, from the early days of Instagram and Snapchat to the future of immersive applications, is a key highlight of the book. He discusses the roles of various technology stakeholders, including internet hosting providers, website developers, cloud computing experts, infrastructure engineers, and the ongoing need for advanced networking and hardware. "Once Upon Tomorrow" is a visionary piece that invites readers to rethink the Metaverse and its limitless potential.
For additional information and to purchase please visit: onceupontomorrow.com
About Shurick Agapitov
As the founder of Xsolla, Inc., Shurick Agapitov is a highly respected innovator and advisor in gaming, Web3, Metaverse, and fintech. His trailblazing video game company integrates blockchain technology, providing developers with advanced tools and services for more effective game operations and sales. With a global presence, including offices in Los Angeles, Berlin, and Seoul, Xsolla, under Shurick’s leadership, is shaping the future of gaming and the Metaverse, fostering a more decentralized and inclusive industry.
For additional information about Shurick Agapitov please visit: themarque.com or LinkedIn.com
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130496363/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom